Vanderbilt University School of Medicine

Fingleton, Barbara Mary , Ph.D.
Assistant Professor of Cancer Biology

Lab Url: N/A

Phone Number: 615-936 5877

Email Address:barbara.fingleton@Vanderbilt.Edu

Fingleton, Barbara's picture

Office Address   Mailing Address

715CA PRB [office]/ 734 PRB [lab]

771 PRB 37232-6840

Research Keywords
Inflammation, Proteolysis, colitis, IL4, IL13, MMP10, colon cancer,Cancer,Enzyme action,Knockout,Malignancy,Mouse

Research Specialty
Understanding function and how to therapeutically target inflammatory molecules in colitis and colon cancer

Research Description
My background is in the area of matrix metalloproteinases (MMPs) and how they contribute to cancer development and progression. I have been especially interested in testing drugs that can inhibit MMPs in cancer models and in understanding why such drugs have not been effective in human cancer patients. Lately, I have focused on some of the roles of specific MMPs in pre-cancerous inflammatory conditions, particularly colitis. We have identified a protective function for a specific MMP in colitis and are currently working on elucidating the mechanism. Additionally, I work on the cytokines IL4 and IL13 and their receptors ,and how these molecules can influence colon cancer development and progression. We use multiple mouse models combined with in vitro approaches to address the pleiotropic functions of these cytokines which affect both the epithelial cancer cells and the inflammatory infiltrate within tumors.

Barrett, CW, Fingleton, B, Williams, A, Ning, W, Fischer, MA, Washington, MK, Chaturvedi, R, Wilson, KT, Hiebert, SW, Williams, CS. MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model. Cancer Res, 71(4), 1302-12, 2011.

Koon, HB, Fingleton, B, Lee, JY, Geyer, JT, Cesarman, E, Parise, RA, Egorin, MJ, Dezube, BJ, Aboulafia, D, Krown, SE. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr, 56(1), 64-8, 2011.

Fingleton, B. Inflammatory proteinase slips into tumor cells. Nat Med, 16(2), 161-3, 2010. PMCID:2902104

Fingleton, B, Lynch, CC. A new dress code for MMPs: cleavage optional. Dev Cell, 18(1), 3-4, 2010.

Koller, FL, Hwang, DG, Dozier, EA, Fingleton, B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis, 31(6), 1010-7, 2010.

Lynch, CC, Vargo-Gogola, T, Matrisian, LM, Fingleton, B. Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA. J Oncol, 2010, 530745, 2010. PMCID:2902104

Ogden, SR, Noto, JM, Allen, SS, Patel, DA, Romero-Gallo, J, Washington, MK, Fingleton, B, Israel, DA, Lewis, ND, Wilson, KT, Chaturvedi, R, Zhao, Z, Shyr, Y, Peek, RM. Matrix metalloproteinase-7 and premalignant host responses in Helicobacter pylori-infected mice. Cancer Res, 70(1), 30-5, 2010.

Stathopoulos, GT, Sherrill, TP, Karabela, SP, Goleniewska, K, Kalomenidis, I, Roussos, C, Fingleton, B, Yull, FE, Peebles, RS, Blackwell, TS. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med, 182(10), 1273-81, 2010. PMCID:2902104

Martin, MD, Carter, KJ, Jean-Philippe, SR, Chang, M, Mobashery, S, Thiolloy, S, Lynch, CC, Matrisian, LM, Fingleton, B. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res, 68(15), 6251-9, 2008.

Martin, MD, Fingleton, B, Lynch, CC, Wells, S, McIntyre, JO, Piston, DW, Matrisian, LM. Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth. Clin Exp Metastasis, 25(8), 877-85, 2008. PMCID:2588650

Ogden, SR, Wroblewski, LE, Weydig, C, Romero-Gallo, J, O''Brien, DP, Israel, DA, Krishna, US, Fingleton, B, Reynolds, AB, Wessler, S, Peek, RM. p120 and Kaiso regulate Helicobacter pylori-induced expression of matrix metalloproteinase-7. Mol Biol Cell, 19(10), 4110-21, 2008. PMCID:2555941

Quarles, CC, Lepage, M, Gorden, DL, Fingleton, B, Yankeelov, TE, Price, RR, Matrisian, LM, Gore, JC, McIntyre, JO. Functional colonography of Min mice using dark lumen dynamic contrast-enhanced MRI. Magn Reson Med, 60(3), 718-26, 2008. PMCID:2646120

Sinnamon, MJ, Carter, KJ, Fingleton, B, Matrisian, LM. Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int J Exp Pathol, 89(6), 466-75, 2008.

Sinnamon, MJ, Carter, KJ, Sims, LP, Lafleur, B, Fingleton, B, Matrisian, LM. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis, 29(4), 880-6, 2008.

Stathopoulos, GT, Sherrill, TP, Han, W, Sadikot, RT, Polosukhin, VV, Fingleton, B, Yull, FE, Blackwell, TS. Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis, 25(1), 43-51, 2008.

Stathopoulos, GT, Sherrill, TP, Han, W, Sadikot, RT, Yull, FE, Blackwell, TS, Fingleton, B. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res, 6(3), 364-71, 2008.

Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des, 13(3), 333-46, 2007.

Fingleton, B. Molecular targets in metastasis: lessons from genomic approaches. Cancer Genomics Proteomics, 4(3), 211-21, 2007.

Fingleton, B. MMPs as therapeutic targets-Still a viable option. Semin Cell Dev Biol, , , 2007. PMCID:2677300

Fingleton, B, Carter, KJ, Matrisian, LM. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. Cancer Res, 67(10), 4800-6, 2007.

Fingleton, B, Powell, WC, Crawford, HC, Couchman, JR, Matrisian, LM. A Rat Monoclonal Antibody That Recognizes Pro- And Active MMP-7 Indicates Polarized Expression In Vivo. Hybridoma (Larchmt), 26(1), 22-7, 2007.

Gorden, DL, Fingleton, B, Crawford, HC, Jansen, DE, Lepage, M, Matrisian, LM. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer, , , 2007.

Lepage, M, Dow, WC, Melchior, M, You, Y, Fingleton, B, Quarles, CC, P??pin, C, Gore, JC, Matrisian, LM, McIntyre, JO. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol Imaging, 6(6), 393-403, 2007.

Lynch, CC, Vargo-Gogola, T, Martin, MD, Fingleton, B, Crawford, HC, Matrisian, LM. Matrix Metalloproteinase 7 Mediates Mammary Epithelial Cell Tumorigenesis through the ErbB4 Receptor. Cancer Res, 67(14), 6760-7, 2007.

Schwartz, DR, Moin, K, Yao, B, Matrisian, LM, Coussens, LM, Bugge, TH, Fingleton, B, Acuff, HB, Sinnamon, M, Nassar, H, Platts, AE, Krawetz, SA, Linebaugh, BE, Sloane, BF. Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. Mol Cancer Res, 5(5), 443-54, 2007.

Stathopoulos, GT, Sherrill, TP, Cheng, DS, Scoggins, RM, Han, W, Polosukhin, VV, Connelly, L, Yull, FE, Fingleton, B, Blackwell, TS. Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A, 104(47), 18514-9, 2007. PMCID:2141808

Acuff, HB, Carter, KJ, Fingleton, B, Gorden, DL, Matrisian, LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res, 66(1), 259-66, 2006. PMCID:1360653

Acuff, HB, Sinnamon, M, Fingleton, B, Boone, B, Levy, SE, Chen, X, Pozzi, A, Carbone, DP, Schwartz, DR, Moin, K, Sloane, BF, Matrisian, LM. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res, 66(16), 7968-75, 2006.

Fingleton, B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci, 11, 479-91, 2006.

Chen, X, Su, Y, Fingleton, B, Acuff, H, Matrisian, LM, Zent, R, Pozzi, A. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int J Cancer, 116(1), 52-61, 2005.

Chen, X, Su, Y, Fingleton, B, Acuff, H, Matrisian, LM, Zent, R, Pozzi, A. An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice. Clin Exp Metastasis, 22(2), 185-93, 2005.

Harrell, PC, McCawley, LJ, Fingleton, B, McIntyre, JO, Matrisian, LM. Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. Exp Cell Res, 303(2), 308-20, 2005.

Lynch, CC, Hikosaka, A, Acuff, HB, Martin, MD, Kawai, N, Singh, RK, Vargo-Gogola, TC, Begtrup, JL, Peterson, TE, Fingleton, B, Shirai, T, Matrisian, LM, Futakuchi, M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell, 7(5), 485-96, 2005.

Fingleton, B, Menon, R, Carter, KJ, Overstreet, PD, Hachey, DL, Matrisian, LM, McIntyre, JO. Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. Clin Cancer Res, 10(23), 7865-74, 2004.

Gustavson, MD, Crawford, HC, Fingleton, B, Matrisian, LM. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. Mol Carcinog, 41(3), 125-39, 2004.

Hulboy, DL, Gautam, S, Fingleton, B, Matrisian, LM. The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. Oncol Rep, 12(1), 13-7, 2004.

McIntyre, JO, Fingleton, B, Wells, KS, Piston, DW, Lynch, CC, Gautam, S, Matrisian, LM. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J, 377(Pt 3), 617-28, 2004. PMCID:1223892

Mohammed, FF, Smookler, DS, Taylor, SE, Fingleton, B, Kassiri, Z, Sanchez, OH, English, JL, Matrisian, LM, Au, B, Yeh, WC, Khokha, R. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet, 36(9), 969-77, 2004.

Yang, L, DeBusk, LM, Fukuda, K, Fingleton, B, Green-Jarvis, B, Shyr, Y, Matrisian, LM, Carbone, DP, Lin, PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409-21, 2004.

Fingleton, B. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets, 7(3), 385-97, 2003.

Fingleton, B. CMT-3. CollaGenex. Curr Opin Investig Drugs, 4(12), 1460-7, 2003.

Coussens, LM, Fingleton, B, Matrisian, LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295(5564), 2387-92, 2002.

Fingleton, B, Vargo-Gogola, T, Crawford, HC, Matrisian, LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia, 3(6), 459-68, 2002. PMCID:1506562

Vargo-Gogola, T, Crawford, HC, Fingleton, B, Matrisian, LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys, 408(2), 155-61, 2002.

Vargo-Gogola, T, Fingleton, B, Crawford, HC, Matrisian, LM. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res, 62(19), 5559-63, 2002.

Crawford, HC, Fingleton, B, Gustavson, MD, Kurpios, N, Wagenaar, RA, Hassell, JA, Matrisian, LM. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol, 21(4), 1370-83, 2001. PMCID:99589

Fingleton, B, Matrisian, LM. Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr Opin Oncol, 13(5), 368-73, 2001.

No?<, V, Fingleton, B, Jacobs, K, Crawford, HC, Vermeulen, S, Steelant, W, Bruyneel, E, Matrisian, LM, Mareel, M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci, 114(Pt 1), 111-118, 2001.

Haro, H, Crawford, HC, Fingleton, B, MacDougall, JR, Shinomiya, K, Spengler, DM, Matrisian, LM. Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J Clin Invest, 105(2), 133-41, 2000. PMCID:377425

Haro, H, Crawford, HC, Fingleton, B, Shinomiya, K, Spengler, DM, Matrisian, LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest, 105(2), 143-50, 2000. PMCID:377426

Nelson, AR, Fingleton, B, Rothenberg, ML, Matrisian, LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18(5), 1135-49, 2000.

Crawford, HC, Fingleton, BM, Rudolph-Owen, LA, Goss, KJ, Rubinfeld, B, Polakis, P, Matrisian, LM. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene, 18(18), 2883-91, 1999.

Fingleton, BM, Heppner Goss, KJ, Crawford, HC, Matrisian, LM. Matrilysin in early stage intestinal tumorigenesis. APMIS, 107(1), 102-10, 1999.

Powell, WC, Fingleton, B, Wilson, CL, Boothby, M, Matrisian, LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol, 9(24), 1441-7, 1999.

Fingleton, B, McDonnell, S. Cytokine regulation of matrilysin gene expression. Biochem Soc Trans, 25(2), 155S, 1997.

McDonnell, S, Fingleton, B. Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors. Cytotechnology, 12(1-3), 367-84, 1993.

Postdoctoral Position Available

Postdoctoral Position Details

Updated Date

Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Copyright 2008 Vanderbilt University School of Medicine
The office of Biomedical Research Education & Training All rights reserved.
For questions or problems concerning this page, please submit a help ticket.